News

Filter

Current filters:

BioMarin Pharmaceutical

1 to 9 of 17 results

BioMarin to acquire Prosensa for up to $840 million

BioMarin to acquire Prosensa for up to $840 million

24-11-2014

US drugmaker BioMarin Pharmaceutical has entered into a definitive agreement to purchase all of the outstanding…

BioMarin PharmaceuticaldrisapersenMergers & AcquisitionsPharmaceuticalProsensaRare diseases

Sanofi and Regeneron purchase FDA priority voucher for alirocumab

Sanofi and Regeneron purchase FDA priority voucher for alirocumab

31-07-2014

French drug major Sanofi and USA-based biotech firm Regeneron Pharmaceuticals intend to use a US Food…

alirocumabBioMarin PharmaceuticalFranceMajorPharmaceuticalRare diseasesRare pediatric diseasesRegeneronRegeneron PharmaceuticalsRegulationSanofiUSA

Extended US market exclusivity for BioMarin's rare disease drug Kuvan

14-04-2014

US drugmaker BioMarin Pharmaceutical says that the Food and Drug Administration has granted Kuvan (sapropterin…

BioMarin PharmaceuticalKuvanNorth AmericaPharmaceuticalRare diseasesRegulationUSA

Positive CHMP opinion for BioMarin’s Vimizim for Morquio A syndrome

Positive CHMP opinion for BioMarin’s Vimizim for Morquio A syndrome

21-02-2014

BioMarin Pharmaceutical says that the European Medicines Agency’s Committee for Medicinal Products…

BioMarin PharmaceuticalEuropePharmaceuticalRare diseasesRegulationVimizim

FDA approves Vimizim to treat rare congenital enzyme disorder

FDA approves Vimizim to treat rare congenital enzyme disorder

17-02-2014

The US Food and Drug Administration on Friday (February 14) approved BioMarin Pharmaceutical’s Vimizim…

BioMarin PharmaceuticalNorth AmericaPharmaceuticalRare diseasesRegulationUSAVimizim

BioMarin buys rights to Repligen preclinical compounds

23-01-2014

BioMarin Pharmaceuticals has entered into an agreement to purchase from fellow USA-based Repligen Corp…

BioMarin PharmaceuticalBiotechnologyLicensingRare diseasesRepligen

FDA committee recommends approval for BioMarin's Vimizim

FDA committee recommends approval for BioMarin's Vimizim

20-11-2013

A US Food and Drug Administration panel has voted in favor of approval of Vimizim for the treatment of…

BioMarin PharmaceuticalNorth AmericaPharmaceuticalRare diseasesRegulationUSAVimizim

1 to 9 of 17 results

Back to top